Skip to main content

MESO · Mesoblast Ltd · Webcasts, Transcripts & Audio

Track MESO — free
$14.23 +0.15 (+1.03%)
Market Cap
$1.96B
Shares
129.85M
Volume · Oct 5 129.86K Avg daily vol (3M) 232.58K

Mesoblast Ltd Webcasts

Earnings calls, investor updates, investor days and conferences for Mesoblast Ltd (MESO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q2
2025-12-31
Mesoblast Ltd (MESO) Q2 2026 Earnings Call Transcript
Confident tone Ryoncil commercial launch and revenue growth rexlemestrocel-L chronic low back pain Phase 3 Revascor for chronic heart failure / LVAD
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-06-30
Mesoblast Ltd (MESO) Q4 2025 Earnings Call Transcript
Confident tone Ryoncil commercial launch Pediatric acute GvHD market Adult GvHD label extension and compassionate use
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q4
2023-06-30
Mesoblast Ltd (MESO) Q4 2023 Earnings Call Transcript
Revenue
$1.93M*
▼ 13.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-03-31
Mesoblast Ltd (MESO) Q3 2023 Earnings Call Transcript
Revenue
$1.94M
▼ 3.6% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-09-30
Mesoblast Ltd (MESO) Q1 2023 Earnings Call Transcript
Revenue
$1.50M
▼ 58.2% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-06-30
Mesoblast Ltd (MESO) Q4 2022 Earnings Call Transcript
Revenue
$2.22M*
▲ 12.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q1
2019-09-30
Mesoblast Ltd (MESO) Q1 2020 Earnings Call Transcript
Revenue
$17.05M
▲ 46.5% YoY
Diluted EPS
$-2.20
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 webcasts
Key facts CIK 1345099 CUSIP 590717401 Visit website Investor relations